Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate.

A paclitaxel/MPEG-PLA block copolymer conjugate was prepared in three steps: (1) hydroxyl-terminated diblock copolymer of monomethoxy-poly(ethylene glycol)-b-poly(lactide) (MPEG-PLA) was synthesized by ring-opening polymerization of L-lactide using MPEG as a maroinitiator; (2) it was converted to carboxyl-terminated MPEG-PLA by reacting with mono-t-butyl ester of diglycolic acid and subsequent deprotecting the t-butyl group with TFA; (3) the latter was reacted with paclitaxel in the presence of dicyclohexylcarbodiimide and dimethylaminopyridine. Structures of the polymers synthesized were confirmed by (1)H NMR, and their molecular weights were determined by gel permeation chromatography. The antitumor activity of the conjugate against human liver cancer H7402 cells was evaluated by MTT method. The results showed that paclitaxel can be released from the conjugate without losing cytotoxicity.

[1]  S. Feng,et al.  Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. , 2003, Biomaterials.

[2]  Chun Xing Li,et al.  Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. , 1998, Cancer research.

[3]  R. Oliyai,et al.  Prodrugs of peptides and proteins for improved formulation and delivery. , 1993, Annual review of pharmacology and toxicology.

[4]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[5]  Y. L. Feng,et al.  Permanent hepatic artery embolization with dextran microspheres in 131 patients with unresectable hepatocellular carcinoma. , 1993, Chinese medical journal.

[6]  M. R. Mejillano,et al.  Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. , 1992, Journal of medicinal chemistry.

[7]  K. Nicolaou,et al.  Design, synthesis and biological activity of protaxols , 1993, Nature.

[8]  J. Thigpen.  Chemotherapy for advanced ovarian cancer: overview of randomized trials. , 2000, Seminars in oncology.

[9]  J. Andersen.  Taxane Anticancer Agents: Basic Science and Current Status.Gunda I. Georg , Thomas T. Chen , Iwao Ojima , Dolatrai M. Vyas , 1997 .

[10]  F. Lee,et al.  Preclinical antitumor activity of water-soluble paclitaxel derivatives , 1997, Cancer Chemotherapy and Pharmacology.

[11]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. , 2004, Current medicinal chemistry.

[12]  R. Liggins,et al.  Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. , 2002, Advanced drug delivery reviews.

[13]  D. Faulds,et al.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. , 1994, Drugs.

[14]  R. Panchagnula.  Pharmaceutical aspects of paclitaxel , 1998 .

[15]  R. Straubinger,et al.  Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes , 1994, Pharmaceutical Research.

[16]  Y. M. Lee,et al.  Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. , 2001, Biomaterials.

[17]  M. Ishitobi,et al.  Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel , 2001, International Journal of Clinical Oncology.

[18]  A. Chang,et al.  Weekly paclitaxel in advanced non-small cell lung cancer. , 2001, Seminars in oncology.

[19]  S. Feng,et al.  Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. , 2004, Biomaterials.

[20]  C. J. Lee,et al.  Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[21]  J. Smith,et al.  Chemotherapy in advanced ovarian cancer. , 1975, National Cancer Institute monograph.

[22]  Kshirsagar.  Drug delivery systems , 2000 .

[23]  R B Greenwald,et al.  Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. , 1996, Journal of medicinal chemistry.

[24]  Y. Lee,et al.  Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. , 2003, Biomaterials.

[25]  J. Gliński,et al.  Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. , 1989, Journal of medicinal chemistry.

[26]  D. Kingston,et al.  Modified Taxols, 6. Preparation of Water-Soluble Prodrugs of Taxol , 1991 .

[27]  C. Conover,et al.  Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. , 1998, Anti-cancer drug design.

[28]  K. Lee,et al.  Antitumor agents 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents. , 2001, Bioorganic & medicinal chemistry.